Literature DB >> 26910458

Ustekinumab in Treatment of Refractory Paediatric Crohn Disease.

F L Cameron1, V Garrick, R K Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26910458     DOI： 10.1097/MPG.0000000000000608

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  5 in total

1.  Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.

Authors:  Judy R Dayan; Michael Dolinger; Keith Benkov; David Dunkin; Jacqueline Jossen; Joanne Lai; Becky L Phan; Nanci Pittman; Marla C Dubinsky
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-07       Impact factor: 2.839

Review 2.  Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.

Authors:  Aranzazu Jauregui-Amezaga; Michael Somers; Heiko De Schepper; Elisabeth Macken
Journal:  Clin Exp Gastroenterol       Date:  2017-11-15

3.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.

Authors:  David R Mack; Eric I Benchimol; Jeff Critch; Jennifer deBruyn; Frances Tse; Paul Moayyedi; Peter Church; Colette Deslandres; Wael El-Matary; Hien Huynh; Prévost Jantchou; Sally Lawrence; Anthony Otley; Mary Sherlock; Thomas Walters; Michael D Kappelman; Dan Sadowski; John K Marshall; Anne Griffiths
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

Review 4.  New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease.

Authors:  Qi-Qi Li; Hui-Hong Zhang; Shi-Xue Dai
Journal:  Front Pediatr       Date:  2022-03-01       Impact factor: 3.418

5.  Ustekinumab for the treatment of refractory pediatric Crohn's disease: a single-center experience.

Authors:  Alexandra Cohen; Najma Ahmed; Ana Sant'Anna
Journal:  Intest Res       Date:  2020-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.